Back to mobile site

Bernstein on Bristol-Myers Squibb Co. (BMY): 'Key Catalysts Carrying More Risk Than Ever'

November 17, 2025 6:25 AM EST Send to a Friend
Bernstein SocGen Group analyst Courtney Breen reiterated a Market Perform rating and $58.00 price target on Bristol-Myers Squibb Co. (NYSE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login